Please login to the form below

Not currently logged in
Email:
Password:

Ipsen appoints executive vice president

Alexandre Lebeaut also set to be chief scientific officer

Alexandre_Lebeaut_IpsenIpsen has appointed Dr Alexandre Lebeaut as its new executive VP, research and development, and chief scientific officer to focus on the firm’s strategy to address unmet medical needs.

Lebeaut joined Ipsen in 2013 as senior VP, chief development officer, global drug development and was appointed interim head of R&D in December 2016.

Prior to joining Ipsen, Lebeaut has held several leadership positions in clinical development and medical affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi and Novartis.

David Meek, CEO of Ipsen, said: “Dr Lebeaut has consistently demonstrated an unwavering commitment to innovation, collaboration and successful execution of drug development strategies.

“During his four years at Ipsen, Dr Lebeaut has been instrumental in successfully leading our global development programmes.

“He will continue to lead the transformation of Ipsen’s R&D strategy to further build a differentiated and sustainable portfolio to continue to address unmet medical needs in our key areas of expertise.”

18th April 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics